Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Abstract N 7-methylguanosine (m7G), one of the most prevalent RNA modifications, has
recently attracted significant attention. The m7G modification actively participates in …

While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …

Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non–small …

Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …

Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation
and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors …

Our understanding of how the RAS protein family, and in particular mutant KRAS, promotes
metabolic dysregulation in cancer cells has advanced substantially over the last decade. In …

Although it has long been deemed “undruggable”, with the development of drugs specifically
binding the KRAS-G12C mutant protein, clinical trials that directly inhibit oncogenic RAS …

The inhibitory receptor PD-1 suppresses T cell activation by recruiting the phosphatase SHP-
2. However, mice with a T-cell-specific deletion of SHP-2 do not have improved antitumor …